Antitumor activity of HPA3P through RIPK3-dependent regulated necrotic cell death in colon cancer

Eugene Cho; Jong-Kook Lee; Eunji Park; Chang Ho Seo; Tudor Luchian; Yoonkyung Park

doi:10.18632/oncotarget.24083

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Antitumor activity of HPA3P through RIPK3-dependent regulated necrotic cell death in colon cancer

Eugene Cho, Jong-Kook Lee, Eunji Park, Chang Ho Seo, Tudor Luchian and Yoonkyung Park _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:7902-7917. https://doi.org/10.18632/oncotarget.24083

Metrics: PDF 1610 views | HTML 2540 views | ?

Abstract

Eugene Cho1, Jong-Kook Lee1, Eunji Park1, Chang Ho Seo2, Tudor Luchian3 and Yoonkyung Park1,4

1Department of Biomedical Science, Chosun University, Gwangju, Korea

2Department of Bioinformatics, Kongju National University, Kongju, Korea

3Department of Physics, Alexandru I. Cuza University, Iasi, Romania

4Research Center for Proteinaceous Materials (RCPM), Chosun University, Gwangju, Korea

Correspondence to:

Yoonkyung Park, email: [email protected]

Keywords: HPA3P; peptide; necroptosis; RIPK3; antitumor activity

Received: July 27, 2017 Accepted: January 02, 2018 Published: January 09, 2018

ABSTRACT

The antimicrobial peptide HPA3 shows anticancer activity in gastric cancer and leukaemia. However, how HPA3 exerts its anticancer activity, as well as whether it also exhibits activity in other cancers, remains unknown. Therefore, the aim of this study was to evaluate the anticancer activity of HPA3 and its analogues in colon cancer and to elucidate the mechanisms responsible for this activity. HPA3P decreased cell viability, whereas HPA3 and HPA3P2 did not decrease cell viability in colon cancer cells compared with control cells. This reduction in cell viability occurred through necrosis, a conclusion supported by our observation of the release of cellular contents, our intracellular PI staining results, and our observation of the release of HMGB1. Moreover, RIPK3 inhibition blocks the reduction of cell viability by HPA3P. Consistent with this finding, we found that knocking down RIPK3 and MLKL, key necroptosis proteins, attenuates the reductions in cell viability induced by HPA3P. Furthermore, HPA3P can improve the anticancer activity of chemotherapeutic agents and exhibits anticancer activity in other cancer cells. These results suggest that HPA3P may have potential as an anticancer agent in the treatment of colon cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24083

Publication Alerts

Research Papers:

Antitumor activity of HPA3P through RIPK3-dependent regulated necrotic cell death in colon cancer

Abstract